Email
Comments
Print-FriendlyApproval of Generic Abacavir Tablets, 300 mg
June 20, 2012
On June 18, 2012, FDA granted approval for a generic formulation of abacavir tablets, 300 mg, manufactured by Mylan Pharmaceuticals, indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.
FDA has determined that the generic formulation is bioequivalent and, therefore, therapeutically equivalent to the reference listed drug, ZiagenTablets, a product of VIIV Healthcare Company.
Approval of this generic formulation means that it may be marketed in the United States.
A complete list of approved generic formulations of antiretroviral drugs used in the treatment of HIV infection is available on the FDA web site.
This article was provided by U.S. Food and Drug Administration. Visit the FDA's website to find out more about their activities and publications.
|
No comments have been made.
|
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)
TheBodyPRO.com: About TheBodyPRO.com | Contact TheBodyPRO.com | Content Policy | Advertise With Us
Remedy Health Media: About Remedy Health Media | Contact Remedy Health Media | Terms of Use | Privacy Policy
TheBodyPRO.com is a service of Remedy Health Media, LLC, 500 5th Avenue, 19th Floor, New York, NY 10110. TheBodyPRO.com and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of TheBodyPRO.com's homepage, topic pages, page designs and HTML code. General Disclaimer: TheBodyPRO.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBodyPRO.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.
